Skip to main content
Erschienen in: Cancer Causes & Control 8/2015

01.08.2015 | Original paper

Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012

verfasst von: Birgitte Baldur-Felskov, Christian Munk, Thor Schütt Svane Nielsen, Christian Dehlendorff, Benny Kirschner, Jette Junge, Susanne K. Kjaer

Erschienen in: Cancer Causes & Control | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The incidence of cervical cancer, including squamous cell carcinoma (SCC), has been decreasing in several developed countries since the onset of organized screening programs; in some countries, however, the incidence of adenocarcinoma has increased among young women. We investigated the Danish incidence trends during 1997–2011 when cervical screening coverage was high. Incidences of cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) were also assessed, with the latest part of the study period coinciding with introduction of free-of-charge human papillomavirus (HPV) vaccination.

Methods

Using nationwide registries, we estimated age-specific and age-standardized incidence rates and estimated annual percentage change (EAPC).

Results

The incidence of SCC decreased significantly, especially in women aged ≥45 years [EAPC: −3.1 % (95 % CI −4.3 to −2.5)], whereas the incidence of adenocarcinoma increased significantly, from 2.4 to 3.1/100,000 primarily due to increases in women aged ≤44 years [EAPC: 4.3 % (95 % CI 1.8–6.7)]. The incidences of CIN3 and AIS increased significantly from 94.7 to 156.5/100,000 and 3.3 to 11.3/100,000, respectively, but, importantly, they decreased significantly during 2009–2012 in women aged ≤20 years.

Conclusions

The Danish screening program has successfully reduced the incidence of cervical cancer, especially of SCC in older women; however, the program has not significantly reduced the incidence in young women or the incidence of adenocarcinoma, which is increasing. Decreases in the incidences of CIN3 and AIS in age groups with high HPV vaccine coverage may herald a future decrease in cervical cancer incidence in young Danish women.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality WORLDWIDE: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed August 2014 Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality WORLDWIDE: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed August 2014
3.
4.
Zurück zum Zitat Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomark Prev 14:677–686CrossRef Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomark Prev 14:677–686CrossRef
5.
Zurück zum Zitat Kyndi M, Frederiksen K, Kruger KS (2006) Cervical cancer incidence in Denmark over six decades (1943–2002). Acta Obstet Gynecol Scand 85:106–111PubMedCrossRef Kyndi M, Frederiksen K, Kruger KS (2006) Cervical cancer incidence in Denmark over six decades (1943–2002). Acta Obstet Gynecol Scand 85:106–111PubMedCrossRef
6.
Zurück zum Zitat Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E (2004) Increasing trends of cervical adenocarcinoma incidence in Central Italy despite extensive screening programme, 1985–2000. Cancer Detect Prev 28:461–464PubMedCrossRef Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E (2004) Increasing trends of cervical adenocarcinoma incidence in Central Italy despite extensive screening programme, 1985–2000. Cancer Detect Prev 28:461–464PubMedCrossRef
8.
Zurück zum Zitat Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A (2009) Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 20:1129–1138. doi:10.1007/s10552-009-9317-z PubMedCrossRef Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A (2009) Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 20:1129–1138. doi:10.​1007/​s10552-009-9317-z PubMedCrossRef
9.
Zurück zum Zitat de Kok IM, van der Aa MA, van Ballegooijen M et al (2011) Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 128:2174–2181. doi:10.1002/ijc.25553 PubMedCrossRef de Kok IM, van der Aa MA, van Ballegooijen M et al (2011) Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 128:2174–2181. doi:10.​1002/​ijc.​25553 PubMedCrossRef
10.
Zurück zum Zitat Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM (2007) Decreasing incidence of cervical adenocarcinoma in Ontario: this related to improved endocervical Pap test sampling? Int J Cancer 120:362–367PubMedCrossRef Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM (2007) Decreasing incidence of cervical adenocarcinoma in Ontario: this related to improved endocervical Pap test sampling? Int J Cancer 120:362–367PubMedCrossRef
11.
Zurück zum Zitat Sigurdsson K (1999) The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78:478–485PubMedCrossRef Sigurdsson K (1999) The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78:478–485PubMedCrossRef
12.
Zurück zum Zitat Lynge E (2002) Cervical cancer screening. Ugeskr Laeger 164:171–173PubMed Lynge E (2002) Cervical cancer screening. Ugeskr Laeger 164:171–173PubMed
15.
Zurück zum Zitat Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907PubMedCrossRef Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907PubMedCrossRef
18.
21.
Zurück zum Zitat Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632PubMedCrossRef Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632PubMedCrossRef
22.
Zurück zum Zitat Castellsague X, Diaz M, de Sanjosé S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315PubMedCrossRef Castellsague X, Diaz M, de Sanjosé S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315PubMedCrossRef
25.
Zurück zum Zitat Kjaer SK, Munk C, Junge J, Iftner T (2014) Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 25:179–189. doi:10.1007/s10552-013-0320-z PubMedCrossRef Kjaer SK, Munk C, Junge J, Iftner T (2014) Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 25:179–189. doi:10.​1007/​s10552-013-0320-z PubMedCrossRef
28.
Zurück zum Zitat Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK (2014) Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:915–922. doi:10.1007/s10552-014-0392-4 PubMedCrossRef Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK (2014) Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:915–922. doi:10.​1007/​s10552-014-0392-4 PubMedCrossRef
29.
Zurück zum Zitat Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014) Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst 106: djt460. doi: 10.1093/jnci/djt460 Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014) Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst 106: djt460. doi: 10.​1093/​jnci/​djt460
34.
Zurück zum Zitat Danske Regioner (2012) Økonomisk vejledning 2008, 2010, 2011 and 2012. http://www.regioner.dk/økonomi/økonomisk+vejledning/baggrundsmappe2007og2008/regionernes+bidrag+til+patobanken+i+2008. Accessed November 2013 Danske Regioner (2012) Økonomisk vejledning 2008, 2010, 2011 and 2012. http://​www.​regioner.​dk/​økonomi/​økonomisk+vejled​ning/​baggrundsmappe20​07og2008/​regionernes+bidr​ag+til+patobanke​n+i+2008.​ Accessed November 2013
36.
Zurück zum Zitat R Development Core Team (2012) R: A language and environment for statistical computing. Auckland: R Foundation for Statistical Computing. Vienna, Austria. http://www.R-project.org. Accessed October 2013 R Development Core Team (2012) R: A language and environment for statistical computing. Auckland: R Foundation for Statistical Computing. Vienna, Austria. http://​www.​R-project.​org. Accessed October 2013
37.
Zurück zum Zitat Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F (2014) 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111:965–969. doi:10.1038/bjc.2014.362 PubMedCrossRef Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F (2014) 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111:965–969. doi:10.​1038/​bjc.​2014.​362 PubMedCrossRef
41.
Zurück zum Zitat Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044PubMedCrossRef Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044PubMedCrossRef
43.
Zurück zum Zitat Dillner J (2000) Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 19:7–23PubMedCrossRef Dillner J (2000) Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 19:7–23PubMedCrossRef
45.
Zurück zum Zitat Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14:2191–2199CrossRef Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14:2191–2199CrossRef
47.
Metadaten
Titel
Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012
verfasst von
Birgitte Baldur-Felskov
Christian Munk
Thor Schütt Svane Nielsen
Christian Dehlendorff
Benny Kirschner
Jette Junge
Susanne K. Kjaer
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 8/2015
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0603-7

Weitere Artikel der Ausgabe 8/2015

Cancer Causes & Control 8/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.